Prevention of hepatitis C virus infection and liver cancer

Recent Results in Cancer Research

Volumn 193, Issue , 2014, Pages 113-133

  Lim, E J ^a   Torresi, J ^a  

^a AUSTIN HOSPITAL   (Australia)

Author keywords

Antiviral treatment; Cirrhosis; Direct acting antiviral agents; Hepatitis C; Hepatocellular carcinoma; Vaccines

Indexed keywords

ABT 072; ASUNAPREVIR; BI 207127; BOCEPREVIR; CHRONVAC C; DACLATASVIR; DANOPREVIR; GI 5005A; HEPATITIS C VACCINE; IC 41; INTERFERON; INTERFERON LAMBDA; LOMIBUVIR; MERICITABINE; MK 5172; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; PROTEINASE INHIBITOR; RECOMBINANT VACCINE; RIBAVIRIN; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; VANIPREVIR; CYCLOPHILIN; DELEOBUVIR; E1 VACCINE; E2 VACCINE; GI 5005A VACCINE; GRAZOPREVIR; IC41 VACCINE; PEGINTERFERON; TG4040 VACCINE;

ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CANCER GROWTH; CANCER PREVENTION; CANCER RISK; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSGEUSIA; GASTROINTESTINAL SYMPTOM; HEALTH CARE QUALITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION PREVENTION; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MIXED INFECTION; MULTIPLE CYCLE TREATMENT; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RASH; RISK REDUCTION; TREATMENT DURATION; VIRAL CLEARANCE; VIRUS REPLICATION; VIRUS TRANSMISSION; LIVER CARCINOGENESIS; MORBIDITY; MORTALITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PUBLIC HEALTH; RISK FACTOR;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER NEOPLASMS;

EID: 84958249920     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-38965-8_7     Document Type: Article

References (87)

1. National institutes of health consensus development conference statement: Management of hepatitis c (2002) (June 10-12, 2002). Gastroenterology, 123(6), 2082-20999
2. Alter MJ (1995) Epidemiology of hepatitis c in the west. Semin Liver Dis 15(1):5-144
3. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R, Investigators HR (2011) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364(13):1207-12177
4. Bartenschlager R, Penin F, Lohmann V, Andre P (2011) Assembly of infectious hepatitis c virus particles. Trends Microbiol 19(2):95-1033
5. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, Cordoba J, Herola A, Ascher N, Mir J, Berenguer J, Wright TL (2000) HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 32(4):673-6844
6. Brainard DM, Petry A, Van Dyck K, Nachbar RB, De Lepeleire IM, Caro L, Stone JA, Sun P, Uhle M, Wagner FD, O'mara E, Wagner JA (2010) Safety and antiviral activity of MK-5172, a novel HCV N53/4a protease inhibitor with potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients. Hepatology 52(4):706A-707AA
7. Bressler BL, Guindi M, Tomlinson G, Heathcote J (2003) High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis c. Hepatology (Baltimore, Md.), vol 38(3) pp 639-444
8. Bruix J, Sherman M, Practice Guidelines Committee A, A. F. T. S. O. L. D. (2005) Management of hepatocellular carcinoma. Hepatology (Baltimore, Md.) 42(5), 1208-12366
9. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegno L, Mazzella G, Ascione A, Santantonio T, Piccinino F, Andreone P, Mangia A, Gaeta GB, Persico M, Fagiuoli S, Almasio PL, Italian Association of the Study of the Liver D (2007) Sustained virological response to interferonalpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology (Baltimore, Md.), 45(3), 579-5877
10. Buhler S, Bartenschlager R (2012) New targets for antiviral therapy of chronic hepatitis c. Liver international: official J Int Assoc Liver, 32 Suppl 1, pp 9-166
11. Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, Mcphee F, Hughes E Kumada H (2012) Dual therapy with the nonstructural protein 5a inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis c virus genotype 1b-infected null responders. Hepatology (Baltimore, Md.) 55(3), 742-7488
12. Chen SL, Morgan TR (2006) The natural history of hepatitis c virus (HCV) infection. Int J Med Sci 3(2):47-522
13. Chevaliez S, Pawlotsky J-M (2007) Hepatitis c virus: virology, diagnosis and management of antiviral therapy. World J Gastroenterology:WJG 13(17):2461-24666
14. Cho LY, Yang JJ, Ko K-P, Park B, Shin A, Lim MK, Oh J-K, Park S, Kim YJ, Shin H-R, Yoo KY, Park SK (2011) Coinfection of hepatitis b and c viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis. Int J Cancer J Int du Cancer 128(1):176-1844
15. Crotty S, Cameron C, Andino R (2002) Ribavirin's antiviral mechanism of action: Lethal mutagenesis? J Molecular Med-Jmm 80(2):86-955
16. Davis GL, Albright JE, Cook SF, Rosenberg DM (2003) Projecting future complications of chronic hepatitis c in the united states. Liver Transpl 9(4):331-3388
17. Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, Matheron S, Le Moing V, Vachon F, Degott C, Valla D, Marcellin P (2001) The influence of human immunodeficiency virus coinfection on chronic hepatitis c in injection drug users: A longterm retrospective cohort study. Hepatology (Baltimore, Md.) 34(6), 1193-11999
18. Dibisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, Kleiner DE, Mahaney K, Hoofnagle JH, Wright D (1995) Ribavirin as therapy for chronic hepatitisc - a randomized, double-blind, placebo-controlled trial. Ann Intern Med 123(12), 8977
19. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, Decarli A, Trevisi P, Ribero ML, Martelli C, Porru S, Nardi G (2002) Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 155(4):323-3311
20. Dore GJ, Law M, Macdonald M, Kaldor JM (2003) Epidemiology of hepatitis c virus infection in Australia. J Clin Virol 26(2):171-1844
21. Drane D, Maraskovsky E, Gibson R, Mitchell S, Barnden M, Moskwa A, Shaw D, Gervase B, Coates S, Houghton M, Basser R (2009) Priming of CD4 and CD8 t cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers. Human vaccines 5(3):151-1577
22. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132(7):2557-25766
23. Flisiak R, Feinman SV, Jablkowski M, Horban A, Kryczka W, Pawlowska M, Heathcote JE, Mazzella G, Vandelli C, Nicolas-Metral V, Grosgurin P, Liz JS, Scalfaro P, Porchet H, Crabbe R (2009) The cyclophilin inhibitor Debio 025 combined with PEG IFnalpha2a significantly reduces viral load in treatment-naive hepatitis c patients. Hepatology (Baltimore, Md.) 49(5), 1460-14688
24. Forns X, Bukh J (1999) The molecular biology of hepatitis c virus. Genotypes and quasispecies. Clinics in liver disease 3(4), 693-716, vii
25. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis c virus infection. The New England J Med 347(13):975-9822
26. Gane EJ, Roberts SK, Stedman CAM, Angus PW, Ritchie B, Elston R, Ipe D, Morcos PN, Baher L, Najera I, Chu T, Lopatin U, Berrey MM, Bradford W, Laughlin M, Shulman NS, Smith PF (2010) Oral combination therapy with a nucleoside polymerase inhibitor (rg7128) and danoprevir for chronic hepatitis c genotype 1 infection (inform-1): a randomised, doubleblind, placebo-controlled, dose-escalation trial. Lancet 376(9751):1467-14755
27. Gane EJ, Rouzier R, Stedman C, Wiercinska-Drapalo A, Horban A, Chang L, Zhang Y, Sampeur P, Najera I, Smith P, Shulman NS, Tran JQ (2011a) Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus peg-IFN alpha-2a/RBV in hepatitis c patients. J Hepatol 55(5):972-9799
28. Gane EJ, Stedman CA, Hyland RH, Sorensen RD, Symonds WT, Hindes R, Berrey MM (2011b) Once daily psi-7977 plus RBV: Pegylated interferon-alfa not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3. Hepatology, 54(377A-377A)
29. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun J-H, O'boyle DR 2nd, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG (2010) Chemical genetics strategy identifies an HCV NS5a inhibitor with a potent clinical effect. Nature 465(7294):96-1000
30. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, Mchutchison JG, Goldstein DB (2009) Genetic variation in IL28b predicts hepatitis c treatment-induced viral clearance. Nature 461(7262):399-4011
31. Hadziyannis SJ, Sette H, Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM & Group, P. I. S. (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis c: A randomized study of treatment duration and ribavirin dose. Anna Intern Med 140(5), 346-555
32. Hagan H, Pouget ER, Des Jarlais DC (2011) A systematic review and meta-analysis of interventions to prevent hepatitis c virus infection in people who inject drugs. J Infect Dis 204(1):74-833
33. Halfon P, Locarnini S (2011) Hepatitis c virus resistance to protease inhibitors. J Hepatol 55(1):192-2066
34. Hanoulle X, Badillo A, Wieruszeski J-M, Verdegem D, Landrieu I, Bartenschlager R, Penin F, Lippens G (2009) Hepatitis c virus NS5a protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins a and b. J Biol Chem 284(20):13589-136011
35. Hayashi J, Aoki H, Kajino K, Moriyama M, Arakawa Y, Hino O (2000) Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor alpha. Hepatology (Baltimore, Md.) 32(5), 958-9611
36. Hino O, Kajino K, Umeda T, Arakawa Y (2002) Understanding the hypercarcinogenic state in chronic hepatitis: a clue to the prevention of human hepatocellular carcinoma. J Gastroenterol 37(11):883-8877
37. Ishikawa T, Higuchi K, Kubota T, Seki K-I, Honma T, Yoshida T, Kamimura T (2012) Combination peg-IFN a-2b/ribavirin therapy following treatment of hepatitis c virusassociated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival. Hepatogastroenterology 59(114):529-5322
38. Jacobson IM, Mchutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, Team AS (2011) Telaprevir for previously untreated chronic hepatitis c virus infection. The New England J Med 364(25):2405-24166
39. Kamal SM, Nasser IA (2008) Hepatitis c genotype 4: What we know and what we don't yet know. Hepatology (Baltimore, Md.), 47(4), 1371-13833
40. Khuroo MS, Khuroo MS, Dahab ST (2004) Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis c genotype 4. Aliment Pharmacol Ther 20(9):931-9388
41. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW (2002) Signaling through the JAK/ STAT pathway, recent advances and future challenges. Gene 285(1-2):1-244
42. Kiyosawa K, Akahane Y, Nagata A, Furuta S (1984) Hepatocellular carcinoma after non-a, non-b posttransfusion hepatitis. Am J Gastroenterology 79(10):777-7811
43. Kohli V, Singhal A, Elliott L, Jalil S (2012) Antiviral therapy for recurrent hepatitis c reduces recurrence of hepatocellular carcinoma following liver transplantation. Transplant Int: official Journal of the European Society for Organ Transplantation 25(2):192-2000
44. Kwo PY, Lawitz EJ, Mccone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK (2010) Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis c infection (sprint-1): an open-label, randomised, multicentre phase 22 trial. Lancet 376(9742):705-7166
45. Lagace L, Cartier M, Laflamme G, Lawetz C, Marquis M, Triki I, Bernard M-J, Bethell R, Larrey DG, Lueth S, Trepo C, Stern JO, Boecher WO, Steffgen J, Kukolj G (2010) Genotypic and phenotypic analysis of the NS5b polymerase region from viral isolates of HCV chronically infected patients treated with bi 207127 for 5-days monotherapy. Hepatology 52(4):1205A- 1206A
46. Lalezari J, Lawitz E, Rodriguez-Torres M, Sheikh A, Freilich B, Nelson DR, Hassanein T, Mader M, Albanis E, Symonds W, Berrey MM (2011) Once daily psi-7977 plus pegIFN/RBV in a phase 2b trial: Rapid virologic suppression in treatment-naive patients with HCV GT2/GT3. J Hepatol 54(S28-S28)
47. Lauer GM, Barnes E, Lucas M, Timm J, Ouchi K, Kim AY, Day CL, Robbins GK, Casson DR, Reiser M, Dusheiko G, Allen TM, Chung RT, Walker BD, Klenerman P (2004) High resolution analysis of cellular immune responses in resolved and persistent hepatitis c virus infection. Gastroenterology 127(3):924-9366
48. Law MG, Dore GJ, Bath N, Thompson S, Crofts N, Dolan K, Giles W, Gow P, Kaldor J, Loveday S, Powell E, Spencer J, Wodak A (2003) Modelling hepatitis c virus incidence, prevalence and long-term sequelae in Australia. Int J Epidemiol 32(5):717-7244
49. Li X, Hui A-M, Sun L, Hasegawa K, Torzilli G, Minagawa M, Takayama T, Makuuchi M (2004) P16INK4a hypermethylation is associated with hepatitis virus infection, age, and gender in hepatocellular carcinoma. Clinical Cancer Res: Official J Am Assoc Cancer Res 10(22):7484-74899
50. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim H.-Y, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky H. L, Dienstag JL, Ghany MG, Morishima C, Morgan TR & Group H.-C. T (2011) Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis c. Gastroenterology, 140(3), 840-849; quiz e122
51. Lok AS, Seeff LB, Morgan TR, Di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman Z D & Group, H.-C. T. (2009) Incidence of hepatocellular carcinoma and associated risk factors in hepatitis c-related advanced liver disease. Gastroenterology, 136(1), 138-1488
52. Manns MP, Mchutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling MH, Albrecht JK, & Int Hepatitis Interventional, T (2001) Peginterferon alfa- 2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis c: A randomised trial. Lancet, 358(9286), 958-9655
53. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, Benhamou JP, Degott C, Erlinger S (1997) Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis c and sustained response to interferon-alpha therapy. Ann Intern Med 127(10):875-8811
54. Maruoka D, Imazeki F, Arai M, Kanda T, Fujiwara K, Yokosuka O (2012) Long-term cohort study of chronic hepatitis c according to interferon efficacy. J Gastroenterol Hepatol 27(2):291-2999
55. Mchutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, Mcnair L, Alam J, Muir AJ (2009a) Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection (vol 360, pg 1827, 2009). New England J Med 361(15), 1516-15166
56. Mchutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, Mccone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, Team IS (2009b) Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis c infection. The New England J Med 361(6):580-5933
57. Mendenhall CL, Seeff L, Diehl AM, Ghosn SJ, French S W, Gartside PS, Rouster SD, Buskell- Bales Z, Grossman CJ, Roselle GA (1991) Antibodies to hepatitis b virus and hepatitis c virus in alcoholic hepatitis and cirrhosis: Their prevalence and clinical relevance. The VA cooperative study group (no. 119). Hepatology (Baltimore, Md.) 14(4 Pt 1), 581-5899
58. Nelson DR, Lalezari J, Lawitz E, Hassanein T, Kowdley K, Poordad F, Sheikh A, Afdhal N, Bernstein D, Dejesus E, Freilich B, Dieterich D, Jacobson I, Jensen D, Abrams GA, Darling J, Rodriguez-Torres M, Reddy R, Sulkowski M, Bzowej N, Demicco M, Strohecker J, Hyland R, Mader M, Albanis E, Symonds WT, Berrey MM (2011) Once daily psi-7977 plus peg-IFN/ RBV in HCV GT1: 98% rapid virologic response, complete early virologic response: The proton study. J Hepatology, 54(S544-S544)
59. Parkin DM (2001) Global cancer statistics in the year. Lancet Oncol 2(9):533-5433
60. Patel K, Muir AJ, Mchutchison JG (2006) Diagnosis and treatment of chronic hepatitis c infection. BMJ (Clinical research ed.) 332(7548):1013-10177
61. Patterson JL, Fernandezlarsson R (1990) Molecular mechanisms of action of ribavirin. Rev Infect Dis 12(6):1139-11466
62. Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, Cosset F.-L, Patel AH, Meisel H, Baumert J, Viazov S, Rispeter K, Blum HE, Roggendorf M, Baumert TF (2007) Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Nat Acad Sci United States Am 104(14), 6025-60300
63. Pockros P, Jensen D, Tsai N, Taylor RM, Ramji A, Cooper C, Dickson R, Tice A, Stancic S, Ipe D, Thommes JA, Vierling JM (2011) First svr data with the nucleoside analogue polymerase inhibitor mericitabine (rg7128) combined with peginterferon/ribavirin in treatment-naive HCV G1/4 patients: Interim analysis from the jump-c trial. J Hepatology, 54(S538-S538)
64. Pol S, Ghalib RH, Rustgi V, Martorell C, Everson G, Tatum H, Hezode C, Lim J, Bronowicki J.- P, Abrams G, Brau N, Morris D, Thuluvath P, Reindollar R, Yin P, Diva U, Hindes R, Mcphee F, Gao M, Thiry A, Schnittman S, Hughes E (2011) First report of SVR12 for a NS5a replication complex inhibitor, BMS-790052 in combination with peg-IFN-alfa-2a and RBV: Phase 2a trial in treatment-naive HCV-genotype 1 subjects. 46th annual meeting of the European association for the study of the liver (easl 2011). J Hepatol 54, Suppl. 1 (S544- S545)
65. Poordad F, Mccone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, Dinubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki J-P, Investigators S (2011) Boceprevir for untreated chronic HCV genotype 11 infection. N Engl J Med 364(13):1195-12066
66. Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis c. The obsvirc, metavir, clinivir, and dosvirc groups. Lancet 349(9055):825-8322
67. Pradat P, Tillmann HL, Sauleda S, Braconier JH, Saracco G, Thursz M, Goldin R, Winkler R, Alberti A, Esteban JI, Hadziyannis S, Rizzetto M, Thomas H, Manns MP, Trepo C, Grp H (2007) Long-term follow-up of the hepatitis C HENCORE cohort: Response to therapy and occurrence of liver-related complications. J Viral Hepatitis 14(8):556-5633
68. Raimondi S, Bruno S, Mondelli MU, Maisonneuve P (2009) Hepatitis c virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol 50(6):1142-11544
69. Razali K, Thein HH, Bell J, Cooper-Stanbury M, Dolan K, Dore G, George J, Kaldor J, Karvelas M, Li J, Maher L, Mcgregor S, Hellard M, Poeder F, Quaine J, Stewart K, Tyrrell H, Weltman M, Westcott O, Wodak A, Law M (2007) Modelling the hepatitis c virus epidemic in Australia. Drug Alcohol Depend 91(2-3):228-2355
70. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, Corpas R, Cruz M, Grande L, Vazquez L, Munoz-De-Rueda P, Lopez-Serrano P, Gila A, Gutierrez ML, Perez C, Ruiz-Extremera A, Suarez E, Castillo J (2005) Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis c patients. Gastroenterology 128(3):636-6411
71. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, Poupon R (1998) Determinants of outcome of compensated hepatitis c virus-related cirrhosis. Hepatology (Baltimore, Md.) 27(5), 1435-14400
72. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N., Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky J.-M, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel H.-J, Viazov S, Weiner AJ, Widell A (2005) Consensus proposals for a unified system of nomenclature of hepatitis c virus genotypes. Hepatology (Baltimore, Md.) 42(4), 962-9733
73. Singal AK, Freeman DH Jr, Anand BS (2010a) Meta-analysis: Interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther 32(7):851-8588
74. Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo Y-F, Sood GK (2010b) Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis c virusrelated cirrhosis. Clinical Gastroenterology Hepatology:Official Clinical Prac J Am Gastroenterological Assoc 8(2):192-1999
75. Sommereyns C, Paul S, Staeheli P, Michiels T (2008) IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 4(3):e10000177
76. Streeter DG, Witkowsk Jt, Khare GP, Sidwell RW, Bauer R J, Robins RK, Simon LN (1973) Mechanism of action of 1-beta-d-ribofuranosyl-1,2,4-triazole-3- carboxamide (virazole) - new broad-spectrum antiviral agent. Proc Nat Acad Sci United States Am 70(4), 1174-11788
77. Sun C-A, Wu D-M, Lin C-C, Lu S-N, You S-L, Wang L-Y, Wu M-H, Chen C-J (2003) Incidence and cofactors of hepatitis c virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol 157(8):674-6822
78. Takeyasu M, Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H (2012) Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma. J Med Virol 84(8):1199-12077
79. Thomas H, Foster G, Platis D (2003) Mechanisms of action of interferon and nucleoside analogues. J Hepatology, 39 Suppl 1(S93-8)
80. Thomas MB, Zhu AX. 2005 Hepatocellular carcinoma: the need for progress J Clinical Oncology: Official J Am Society Clinical Oncology 23.13:2892-28999
81. Torresi J, Johnson D, Wedemeyer H (2011) Progress in the development of preventive and therapeutic vaccines for hepatitis c virus. J Hepatol 54(6):1273-12855
82. Vajdy M, Selby M, Medina-Selby A, Coit D, Hall J, Tandeske L, Chien D, Hu C, Rosa D, Singh M, Kazzaz J, Nguyen S, Coates S, Ng P, Abrignani S, Lin Y-L, Houghton M, O'hagan DT (2006) Hepatitis c virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. J Gen Virol 87(Pt 8):2253-22622
83. Wang P, Heitman J (2005) The cyclophilins. Genome Biol 6(7):2266
84. Wiley TE, Mccarthy M, Breidi L, Layden TJ (1998) Impact of alcohol on the histological and clinical progression of hepatitis c infection. Hepatology (Baltimore, Md.) 28(3), 805-99
85. Yu J-W, Wang G-Q, Sun L-J, Li X-G, Li S-C (2007) Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 22(6):832-8366
86. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Muellhaupt B, Pockros P, Terg R, Shouval D, Van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M, Team RS (2011a) Telaprevir for retreatment of HCV infection. N Engl J Med 364(25):2417-24288
87. Zeuzem S, Arora S, Bacon B, Box T, Charlton M, Diago M, Dieterich D, Esteban Mur R, Everson GT, Fallón M, Ferenci P, Flisiak R, George J, Ghalib R, Gitlin N, Gladysz A, Gordon S, Greenbloom S, Hassanein T, Jacobson I, Jeffers L, Kowdley K, Lawitz E, Lee S, Leggett B, Lueth S, Nelson D, Pockros P, Rodriguez-Torres M, Rustgi V, Serfaty L, Sherman M, Shiffman M, Sola R, Sulkowski M, Vargas H, Vierling J, Yoffe B, Ishak L, Fontana D, Xu D, Lester J, Gray T, Horga A, Hillson J, Ramos E, Lopez-Talavera JC, Muir A (2011b) Pegylated interferon-lambda (pegIFN-l) shows superior viral response with improved safety and tolerability versus pegIFNa-2a in HCV patients (G1/2/3/4): Emerge phase IIb through week 12. J Hepatol, 54 Suppl. 1(S538-S539))